UT-Southwestern Medical Center: Semaglutide Lowers Cardiovascular Risk Regardless of Blood Sugar
June 25, 2024
June 25, 2024
DALLAS, Texas, June 25 (TNSres) -- The University of Texas Southwestern Medical Center issued the following news release:
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to a clinical trial including researchers from UT Southwestern Medical Center. The findings, published in Diabetes Care, also . . .
A weekly dose of semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACEs) in people with overweight or obesity and cardiovascular disease but not diabetes, regardless of blood sugar level, according to a clinical trial including researchers from UT Southwestern Medical Center. The findings, published in Diabetes Care, also . . .